

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) (E)-2-(5-Chlorothiophen-2-yl)-N-((3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl)ethanesulfonamide in substantially crystalline form having an X-ray powder diffraction pattern expressed in terms of 2 theta angles and obtained with a diffractometer, wherein said X-ray powder diffraction pattern comprises 2 theta angles at one or more positions selected from the group consisting of 9.1-9.2 ( $\pm 0.1$ ), 16.0-16.1 ( $\pm 0.1$ ), 18.0-18.2 ( $\pm 0.1$ ), and 18.3-18.4 ( $\pm 0.1$ ) degrees.
2. (Original) The substantially crystalline form as claimed in claim 1 in the form of needle-shaped crystals.
3. (Original) The substantially crystalline form as claimed in claim 1 in the form of lath-shaped crystals.
4. (Original) The substantially crystalline form as claimed in claim 1 in the form of a mixture of needle-shaped and lath-shaped crystals.
5. (Previously Presented) The substantially crystalline form as claimed in claim 1 wherein the melting point is greater than 160°C.
6. (Currently Amended) The substantially crystalline form as claimed in claim 1 having an X-ray powder diffraction pattern expressed in terms of 2 theta angles and obtained with a diffractometer, wherein said X-ray powder diffraction pattern comprises 2 theta angles at ~~[[one]]~~ two or more positions selected from the group consisting of 9.1-9.2 ( $\pm 0.1$ ), 16.0-16.1 ( $\pm 0.1$ ), 18.0-18.2 ( $\pm 0.1$ ), and 18.3-18.4 ( $\pm 0.1$ ) degrees.

7. (Currently Amended) The substantially crystalline form as claimed in claim 1 having an X-ray powder diffraction pattern expressed in terms of 2 theta angles and obtained with a diffractometer, wherein said X-ray powder diffraction pattern comprises 2 theta angles at ~~[[one]] three~~ or more positions selected from the group consisting of ~~9.21 ± 0.05, 13.79 ± 0.05, 16.11 ± 0.05, 18.11 ± 0.05, and 18.39 ± 0.05 degrees~~ 9.1-9.2 (±0.1), 16.0-16.1 (±0.1), 18.0-18.2 (±0.1), and 18.3-18.4 (±0.1) degrees.
8. (Currently Amended) The substantially crystalline form as claimed in claim 1 having an X-ray powder diffraction pattern expressed in terms of 2 theta angles and obtained with a diffractometer, wherein said X-ray powder diffraction pattern comprises 2 theta angles at ~~one or more~~ all four positions selected from the group consisting of ~~9.1 ± 0.1, 16.0 ± 0.1, 18.0 ± 0.1, and 18.3 ± 0.1 degrees~~ 9.1-9.2 (±0.1), 16.0-16.1 (±0.1), 18.0-18.2 (±0.1), and 18.3-18.4 (±0.1) degrees.
9. (Canceled)
10. (Canceled).
11. (Canceled).
12. (Canceled).
13. (Previously Presented) A method for the preparation of (E)-2-(5-chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethanesulfonamide in substantially crystalline form which method comprises crystallisation of (E)-2-(5-chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethanesulfonamide from an organic solution, optionally in the presence of water.
14. (Original) A method as claimed in claim 13 wherein the organic solution selected from: an aromatic hydrocarbon, a cycloalkane, an ester, an alcohol or a ketone, or a mixture thereof.
15. (Cancelled).

16. (Cancelled).

17. (Cancelled).

18. (Cancelled).